The company’s partner Adartis Animal Health has placed a first order for the veterinary products that Enzymatica launched in the United States and Canada in July 2014.
The order includes Kalvatin products to a value of about SEK 3 million. According to Enzymatica the order is expected to cover market needs for the next six to twelve months. The first part delivery will be made in the fourth quarter of 2014 and is expected to have a positive impact on earnings of more than SEK 1 million.
“Our partner has recently started the work of introduction and the market is in the build-up phase. We look forward to following the activities in the market during the coming fall and winter. Veterinary products broaden our product portfolio and provide a long term opportunity to grow in a new segment,” says Christian W. Jansson, acting CEO of Enzymatica.
The Kalvatin products are enzyme-based products for treating skin and gum infections, primarily in dogs and cats and are marketed and sold in North America by Enzymatica’s partner Adartis Animal Health.
Read more: Enzymatica sets up subsidiary in the USA